S&P 500   4,122.47
DOW   32,774.41
QQQ   317.08
Are Medtronic And Intuitive Surgical Poised For Big Growth?
Investor Alert: Argentina Loaded With "White Gold" Opportunity (Ad)
'The Sacrifice Zone': Myanmar bears cost of green energy
Is Sofi Financial Stock Finally Ready to Pay Off for Investors?
Ralph Lauren Is A Retail Stock You Can Buy And Hold
The "Trojan Horse" Hiding Inside Of Biden's $2 Trillion Infrastructure Bill. (Ad)
Closing prices for crude oil, gold and other commodities
Learning from failures: How Biden scored win on climate plan
Most electric vehicles won't qualify for federal tax credit
Investor Alert: Argentina Loaded With "White Gold" Opportunity (Ad)
S&P 500   4,122.47
DOW   32,774.41
QQQ   317.08
Are Medtronic And Intuitive Surgical Poised For Big Growth?
Investor Alert: Argentina Loaded With "White Gold" Opportunity (Ad)
'The Sacrifice Zone': Myanmar bears cost of green energy
Is Sofi Financial Stock Finally Ready to Pay Off for Investors?
Ralph Lauren Is A Retail Stock You Can Buy And Hold
The "Trojan Horse" Hiding Inside Of Biden's $2 Trillion Infrastructure Bill. (Ad)
Closing prices for crude oil, gold and other commodities
Learning from failures: How Biden scored win on climate plan
Most electric vehicles won't qualify for federal tax credit
Investor Alert: Argentina Loaded With "White Gold" Opportunity (Ad)
S&P 500   4,122.47
DOW   32,774.41
QQQ   317.08
Are Medtronic And Intuitive Surgical Poised For Big Growth?
Investor Alert: Argentina Loaded With "White Gold" Opportunity (Ad)
'The Sacrifice Zone': Myanmar bears cost of green energy
Is Sofi Financial Stock Finally Ready to Pay Off for Investors?
Ralph Lauren Is A Retail Stock You Can Buy And Hold
The "Trojan Horse" Hiding Inside Of Biden's $2 Trillion Infrastructure Bill. (Ad)
Closing prices for crude oil, gold and other commodities
Learning from failures: How Biden scored win on climate plan
Most electric vehicles won't qualify for federal tax credit
Investor Alert: Argentina Loaded With "White Gold" Opportunity (Ad)
S&P 500   4,122.47
DOW   32,774.41
QQQ   317.08
Are Medtronic And Intuitive Surgical Poised For Big Growth?
Investor Alert: Argentina Loaded With "White Gold" Opportunity (Ad)
'The Sacrifice Zone': Myanmar bears cost of green energy
Is Sofi Financial Stock Finally Ready to Pay Off for Investors?
Ralph Lauren Is A Retail Stock You Can Buy And Hold
The "Trojan Horse" Hiding Inside Of Biden's $2 Trillion Infrastructure Bill. (Ad)
Closing prices for crude oil, gold and other commodities
Learning from failures: How Biden scored win on climate plan
Most electric vehicles won't qualify for federal tax credit
Investor Alert: Argentina Loaded With "White Gold" Opportunity (Ad)
NASDAQ:KPRX

Kiora Pharmaceuticals - KPRX Price Target & Analyst Ratings

$0.15
0.00 (0.00%)
(As of 08/9/2022 12:00 AM ET)
Add
Compare
Today's Range
$0.15
$0.16
50-Day Range
$0.15
$0.48
52-Week Range
$0.14
$2.34
Volume
2.90 million shs
Average Volume
670,107 shs
Market Capitalization
$2.02 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$1.75

Kiora Pharmaceuticals Consensus Rating and Price Target (2022)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Analyst Rating

Buy
Based on 2 Analyst Ratings

Consensus Analyst Price Target

$1.75
1,034.15% Upside
High Prediction$2.50
Average Prediction$1.75
Low Prediction$1.00
TypeCurrent
8/10/21 to 8/10/22
1 Month Ago
7/11/21 to 7/11/22
3 Months Ago
5/12/21 to 5/12/22
1 Year Ago
8/10/20 to 8/10/21
Consensus Rating
Buy
Buy
Buy
N/A
Strong Buy
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
N/A
Buy
2 Buy rating(s)
2 Buy rating(s)
2 Buy rating(s)
N/A
Hold
0 Hold rating(s)
0 Hold rating(s)
0 Hold rating(s)
N/A
Sell
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
N/A
Consensus Price Target$1.75$1.75$2.75N/A
Predicted Upside1,034.15% Upside231.75% Upside304.44% UpsideN/A
Get Kiora Pharmaceuticals Upgrade and Downgrade Alerts

Sign-up to receive the latest news and ratings for KPRX and its competitors with MarketBeat's FREE daily newsletter.


KPRX Analyst Ratings By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

KPRX Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

Kiora Pharmaceuticals Stock vs. The Competition

TypeKiora PharmaceuticalsMedical CompaniesS&P 500
Consensus Rating Score
3.00
2.71
2.50
Consensus RatingBuyBuyHold
Predicted Upside1,034.15% Upside751.27% Upside18.99% Upside
News Sentiment RatingNeutral News
Neutral News
Neutral News
MarketBeat
Community Rating
Outperform Votes
2
50.00%
Underperform Votes
2
50.00%
Avg. Outperform Votes
166
66.67%
Avg. Underperform Votes
83
33.33%
Avg. Outperform Votes
840
68.68%
Avg. Underperform Votes
383
31.32%

Historical Target Prices and Ratings

DateBrokerageAnalyst NameActionRatingPrice TargetUpside/Downside on Report DateDetails
7/11/2022HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetBuy$3.00 ➝ $2.50+449.44%
5/26/2022Maxim Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower Target$1.00+149.93%
(Data available from 8/10/2017 forward. View 10+ years of historical ratings with our analyst ratings screener.)












KPRX Price Target - Frequently Asked Questions

What is Kiora Pharmaceuticals's consensus rating and price target?

According to the issued ratings of 2 analysts in the last year, the consensus rating for Kiora Pharmaceuticals stock is Buy based on the current 2 buy ratings for KPRX. The average twelve-month price prediction for Kiora Pharmaceuticals is $1.75 with a high price target of $2.50 and a low price target of $1.00. Learn more on KPRX's analyst rating history.

Do Wall Street analysts like Kiora Pharmaceuticals more than its competitors?

Analysts like Kiora Pharmaceuticals more than other Medical companies. The consensus rating score for Kiora Pharmaceuticals is 3.00 while the average consensus rating score for medical companies is 2.71. Learn more on how KPRX compares to other companies.

Do MarketBeat users like Kiora Pharmaceuticals more than its competitors?

MarketBeat users like Kiora Pharmaceuticals less than other Medical companies. 50.00% of MarketBeat users gave Kiora Pharmaceuticals an outperform vote while medical companies recieve an average of 66.80% outperform votes by MarketBeat users.

Does Kiora Pharmaceuticals's stock price have much upside?

According to analysts, Kiora Pharmaceuticals's stock has a predicted upside of 231.75% based on their 12-month price targets.

What analysts cover Kiora Pharmaceuticals?

Kiora Pharmaceuticals has been rated by HC Wainwright, and Maxim Group in the past 90 days.


Stock Ratings Reports and Tools

This page (NASDAQ:KPRX) was last updated on 8/10/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.